Neumora Therapeutics is trading at $0.42, up 19.38%, with no clear company-specific catalyst; biotech-sector strength may be contributing. - Biotech ETF XBI rose 2.20% in regular trading, while major indexes were mixed. - Separate news that Johnson & Johnson halted development of a related depression drug and Stifel downgraded Neumora does not explain the rise. - No volume data was provided, so trading activity cannot be assessed.